Descriptor
| Drug Therapy | 2 |
| Mental Retardation | 2 |
| Seizures | 2 |
| Comparative Analysis | 1 |
| Cost Effectiveness | 1 |
| Costs | 1 |
| Institutionalized Persons | 1 |
| Outcomes of Treatment | 1 |
Source
| Mental Retardation | 2 |
Publication Type
| Journal Articles | 2 |
| Reports - Research | 2 |
Education Level
Audience
| Researchers | 1 |
Location
Laws, Policies, & Programs
Assessments and Surveys
What Works Clearinghouse Rating
Peer reviewedVadney, V.; And Others – Mental Retardation, 1994
This study evaluated effects on 77 institutionalized patients with mental retardation of changing from anticonvulsant Depakote to the similar drug, Depakene. Results showed no changes in seizure control, less lethargy on Depakene, but some increase in diarrhea and some changes in psychiatric symptoms. Substantial cost savings were achieved by the…
Descriptors: Cost Effectiveness, Drug Therapy, Institutionalized Persons, Mental Retardation
Peer reviewedVadney, Victor J.; Kraushaar, Kevin W. – Mental Retardation, 1997
Comparison of brand-name Depakene with generic valproic acid medication to control seizures in 64 subjects with mental retardation living in an intermediate care facility found no statistically significant differences in seizures or blood levels. Results suggest use of the generic medication can result in substantial cost savings. (Author/DB)
Descriptors: Comparative Analysis, Costs, Drug Therapy, Mental Retardation
